Heinzelmann M, Mercer-Jones M, Cheadle W G, Polk H C
Price Institute of Surgical Research, Department of Surgery, University of Louisville, School of Medicine, Kentucky 40292, USA.
Ann Surg. 1996 Jul;224(1):91-6. doi: 10.1097/00000658-199607000-00014.
The authors determined the correlation between monocyte CD14 expression and outcome in severely injured patients.
Human leukocyte antigen-DR (HLA-DR) expression CD14 positive monocytes correlates with the development of major infection and subsequent death in severely injured patients. Recent studies show that CD14 is not only a marker for mature monocytes, but also is an important endotoxin/lipopolysaccharide receptor.
Flow cytometry data obtained by dual staining techniques (CD14 and HLA-DR) of monocytes in 213 severely injured patients were analyzed over a 30-day period. Outcome criteria included survival and the development of both major and minor infections.
The percentage of cells expressing CD14 (%CD14) correlated with clinical outcome, reaching significance (p < 0.05) between noninfected survivors (n = 74) and nonsurvivors (n = 21) at days 3, 7, 11, 17, 24, and 30. At days 3, 7, and 17, the %CD14 also was different between noninfected and infected survivors. After 7 days, differences were only seen between survivors and nonsurvivors (p < 0.05). The mean fluorescence intensity (MC CD14) in monocytes of all patients was significantly reduced at day 3 compared with day 1 and remained low for 30 days (p < 0.05). The nonsurvivor group had consistently low MC CD14 values, which were significant at day 5 (p < 0.05).
In addition to HLA-DR expression, CD14 expression on monocytes is an indicator of clinical outcome after injury and could represent a more precise target for treatment.
作者确定严重创伤患者单核细胞CD14表达与预后之间的相关性。
人类白细胞抗原-DR(HLA-DR)在CD14阳性单核细胞上的表达与严重创伤患者发生严重感染及随后死亡相关。最近的研究表明,CD14不仅是成熟单核细胞的标志物,还是一种重要的内毒素/脂多糖受体。
对213例严重创伤患者单核细胞采用双染色技术(CD14和HLA-DR)获取的流式细胞术数据进行为期30天的分析。预后标准包括生存情况以及严重和轻度感染的发生情况。
表达CD14的细胞百分比(%CD14)与临床预后相关,在第3、7、11、17、24和30天,未感染幸存者(n = 74)与非幸存者(n = 21)之间达到显著差异(p < 0.05)。在第3、7和17天,未感染和感染幸存者之间的%CD14也存在差异。7天后,仅在幸存者和非幸存者之间观察到差异(p < 0.05)。与第1天相比,所有患者单核细胞的平均荧光强度(MC CD14)在第3天显著降低,并在30天内保持较低水平(p < 0.05)。非幸存者组的MC CD14值一直较低,在第5天具有显著意义(p < 0.05)。
除HLA-DR表达外,单核细胞上的CD14表达是损伤后临床预后的一个指标,可能代表更精确的治疗靶点。